Evaluation of Systolic Function in Heart Failure With Middle Ejection Fraction by 3D Speckle Tracking Imaging

Study Overview
=================
Brief Summary
-----------------
In 2016, the European Heart Association defined the median ejection fraction heart failure for the first time. More research is needed to improve our understanding of this population, so as to make the best clinical decision and improve the prognosis. In this study, 3D-STI was used to evaluate left ventricular systolic function in heart failure with median ejection fraction.

Detailed Description
-----------------
As the final manifestation of cardiovascular disease and the main cause of death, heart failure is one of the important challenges threatening human health in the 21st century. In 2016, the European Heart Association proposed a new classification standard for heart failure. In particular, for the first time, heart failure with median ejection fraction has been clearly defined. These patients have received more and more attention, but there are still relatively few studies on them. More research is needed to improve our understanding of this part of the population in order to make the best clinical decisions and improve the prognosis. 3D speckle tracking technology is a new technology developed on the basis of real-time three-dimensional echocardiography and speckle tracking technology. It is gradually recognized in the evaluation of left ventricular systolic and diastolic function, especially in the evaluation of cardiotoxicity of chemotherapy drugs. At present, the application of 3D-STI in the evaluation of left ventricular systolic function in heart failure with median ejection fraction is limited and needs further study.In this study, 3D-STI was used to evaluate left ventricular systolic function in heart failure with median ejection fraction.

Official Title
-----------------
Evaluation of Left Ventricular Systolic Function in Heart Failure With Middle Ejection Fraction by 3D Speckle Tracking Imaging

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Other: diagnose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meeting the diagnostic and classification criteria of heart failure proposed in the 2016 ESC guidelines for the diagnosis and treatment of acute / chronic heart failure Exclusion Criteria: acute or chronic infectious diseases; COPD, chronic bronchitis, emphysema and other serious lung diseases; Autoimmune diseases; Malignant tumor; Acute, chronic liver disease or other reasons lead to abnormal liver function (transaminase is more than 3 times of normal value); Acute and chronic kidney disease, end-stage renal disease (serum creatinine > 220 μmol/L, or creatinine clearance rate < 30 ml/min); Heart valve disease; Severe arrhythmia; The image quality of echocardiography was poor when it was larger than three sections;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| control<br>patients without heart failure | |
| HF<br>patients with heart failure | Other: diagnose<br>* HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3D-STI measurement indexes | strain values of different sections from 3D-STI | one week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
median ejection fraction, 3D-STI